These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 22717785)
21. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Kim JC; Park EY; Hong SH; Seo SI; Park YH; Hwang TK Int J Urol; 2005 Oct; 12(10):875-80. PubMed ID: 16323980 [TBL] [Abstract][Full Text] [Related]
22. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397 [TBL] [Abstract][Full Text] [Related]
23. OAB without an overactive bladder in the acute prostaglandin E2 rat model. Hokanson JA; Langdale CL; Sridhar A; Grill WM Am J Physiol Renal Physiol; 2017 Nov; 313(5):F1169-F1177. PubMed ID: 28768666 [TBL] [Abstract][Full Text] [Related]
24. Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder? Huseynov A; Telli O; Haciyev P; Okutucu TM; Akinci A; Ozkidik M; Erguder I; Fitoz S; Burgu B; Soygur T Int Braz J Urol; 2022; 48(3):553-560. PubMed ID: 35373950 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of acupuncture for elderly overactive bladder population in Hong Kong: study protocol for a randomized controlled trial. Chan YT; Zhang HW; Guo YQ; Chan TNH; Kwan YK; Lee CK; Ngan K; Lin ZX Trials; 2018 Jul; 19(1):376. PubMed ID: 30005707 [TBL] [Abstract][Full Text] [Related]
26. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491 [TBL] [Abstract][Full Text] [Related]
27. Overactive bladder changes with time: a 5-year longitudinal followup of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels. Chuang FC; Liu HT; Wang LY; Kuo HC J Urol; 2014 Aug; 192(2):458-63. PubMed ID: 24594404 [TBL] [Abstract][Full Text] [Related]
28. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767 [TBL] [Abstract][Full Text] [Related]
29. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. Hsiao SM; Lin HH; Kuo HC PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901 [TBL] [Abstract][Full Text] [Related]
30. Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker. Oktar T; Kocak T; Oner-Iyidogan Y; Erdem S; Seyithanoglu M; Ziylan O; Kocak H J Pediatr Urol; 2013 Oct; 9(5):617-21. PubMed ID: 22789557 [TBL] [Abstract][Full Text] [Related]
31. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle. Dokmeci F; Cetinkaya SE; Seval MM; Dai O Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584 [TBL] [Abstract][Full Text] [Related]
32. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Wang LW; Han XM; Chen CH; Ma Y; Hai B Int Urol Nephrol; 2014 Feb; 46(2):341-7. PubMed ID: 23982767 [TBL] [Abstract][Full Text] [Related]
33. [Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy]. Knippschild S; Frohme C; Olbert P; Hofmann R; Hegele A Urologe A; 2012 Mar; 51(3):379-83. PubMed ID: 21979907 [TBL] [Abstract][Full Text] [Related]
34. Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls. Cheng Y; Mansfield KJ; Allen W; Millard RJ; Burcher E; Moore KH Neurourol Urodyn; 2013 Sep; 32(7):969-73. PubMed ID: 23129360 [TBL] [Abstract][Full Text] [Related]
35. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder. Pennycuff JF; Schutte SC; Hudson CO; Karp DR; Malykhina AP; Northington GM Neurourol Urodyn; 2017 Mar; 36(3):740-744. PubMed ID: 27062604 [TBL] [Abstract][Full Text] [Related]
36. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. Kim JC; Park EY; Seo SI; Park YH; Hwang TK J Urol; 2006 May; 175(5):1773-6; discussion 1776. PubMed ID: 16600756 [TBL] [Abstract][Full Text] [Related]
37. Imbalance of nerve growth factor metabolism in aging women with overactive bladder syndrome. Mossa AH; Cammisotto PG; Shamout S; Campeau L World J Urol; 2021 Jun; 39(6):2055-2063. PubMed ID: 32870355 [TBL] [Abstract][Full Text] [Related]
38. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. Liu HT; Chancellor MB; Kuo HC BJU Int; 2008 Nov; 102(10):1440-4. PubMed ID: 18489524 [TBL] [Abstract][Full Text] [Related]
39. Can urinary nerve growth factor and bladder wall thickness correlation in children have a potential role to predict the outcome of non-monosymptomatic nocturnal enuresis? Telli O; Samancı C; Sarıcı H; Hascıcek AM; Kabar M; Eroglu M J Pediatr Urol; 2015 Oct; 11(5):265.e1-5. PubMed ID: 26051999 [TBL] [Abstract][Full Text] [Related]
40. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. Malone-Lee JG; Al-Buheissi S BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]